Mer­ck emerges as lead bid­der in po­ten­tial Ac­celeron buy­out with deal pos­si­ble this week — re­port

With ru­mors swirling about a po­ten­tial buy­out of biotech Ac­celeron and its lead PAH drug so­tater­cept, mar­ket watch­ers have been keep­ing close tabs on in­dus­try movers and shak­ers due up for an ex­pen­sive bolt-on. Ac­cord­ing to a new re­port, it ap­pears Mer­ck may be the one.

Mer­ck is in “ad­vanced talks” on a deal to ac­quire Cam­bridge, MA-based Ac­celeron in what pre­vi­ous re­ports pegged as a po­ten­tial $11 bil­lion buy­out, the Wall Street Jour­nal re­port­ed Mon­day. A deal could come as ear­ly as this week, ac­cord­ing to the Jour­nal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER